HHS

Harte Hanks is a shrinking direct-mail/customer-experience business whose top line has fallen every year but one since 2021: $195M (2021) → $206M (2022) → $191M (2023) → $185M (2024) → $160M (2025), with FY2025 down 13.9%. The MD&A shows the decline is broad and worst where it matters most — the Revenue Solutions (former Marketing Services) segment collapsed 30.2% to $35.1M, Fulfillment & Logistics fell 9.3%, and Customer Care fell 5.4%. Management is cutting costs to keep pace (labor down 13.8%, operating expenses down 13.1%), which mechanically shrank the 2024 net loss of -$30.3M to just -$811K in 2025 — but that improvement is a smaller-loss story driven by the absence of 2024's ~$40M 'other expenses' and impairments, not by a return to growth. Operating income was a razor-thin $386K (0.2% margin), and the company still generated NEGATIVE operating cash flow of -$1.74M.

The balance sheet is the real problem. Cash fell 43.1% to just $5.58M, while the business burned cash from operations and spent $2.76M on capex. There is no long-term debt (a genuine positive that provides some runway and downside floor), and equity is $20.5M — so at a $16.7M market cap the stock trades below book at ~0.8x. That is optically cheap (P/S 0.1), but cheapness here reflects a deteriorating, low-quality asset, not a mispricing. With only ~$5.6M cash and negative free cash flow, the margin for error is very thin; another weak year pressures liquidity or forces dilution/asset sales.